CTEV trades 33.4% below Wall Street's consensus target of $39.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CTEV achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 19, 2026, Claritev Corporation (CTEV) has a Wall Street consensus price target of $39.25, based on estimates from 4 covering analysts. With the stock currently trading at $29.42, this represents a potential upside of +33.4%. The company has a market capitalization of $502M.
Analyst price targets range from a low of $28.00 to a high of $61.00, representing a 84% spread in expectations. The median target of $34.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CTEV trades at a trailing P/E of -1.7x. Analysts expect EPS to grow +6.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
EHTHeHealth, Inc. | $51M | $1.65 | — | — | — | — | — |
HIMSHims & Hers Health, Inc. | $7.8B | $35.47 | $28.08 | -20.8% | Hold | — | 20 |
TDOCTeladoc Health, Inc. | $1.5B | $8.07 | $7.40 | -8.3% | Hold | — | 42 |
EXLSExlService Holdings, Inc. | $4.1B | $25.93 | $40.25 | +55.2% | Buy | 11.6x | 19 |
PGNYProgyny, Inc. | $2.0B | $26.08 | $30.33 | +16.3% | Buy | 20.4x | 20 |
UNHUnitedHealth Group Incorporated | $363.9B | $400.96 | $425.81 | +6.2% | Buy | 21.8x | 52 |
CVSCVS Health Corporation | $125.4B | $98.32 | $103.64 | +5.4% | Buy | 13.3x | 41 |
CICigna Corporation | $73.6B | $279.27 | $340.91 | +22.1% | Buy | 9.2x | 39 |
HUMHumana Inc. | $43.3B | $360.65 | $298.50 | -17.2% | Hold | 40.8x | 44 |
MCKMcKesson Corporation | $90.2B | $750.63 | $994.86 | +32.5% | Buy | 17.0x | 31 |
Quick answers to the most common questions about buying CTEV stock.
The consensus Wall Street price target for CTEV is $39.25, representing 33.4% upside from the current price of $29.42. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CTEV has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $39.25 implies 33.4% upside from current levels.
CTEV's current price is $29.42 with a consensus target of $39.25 (33.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $61 for CTEV, while the most conservative target is $28. The consensus of $39.25 represents the median expectation. These targets typically reflect 12-month expectations.
CTEV is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CTEV stock forecast based on 4 Wall Street analysts shows a consensus price target of $39.25, with estimates ranging from $28 (bear case) to $61 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CTEV, with a "Buy" consensus rating and $39.25 price target (33.4% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CTEV analyst price targets range from $28 to $61, a 84% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39.25 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.